UCB (company)

From WikiMD's WELLNESSPEDIA

(Redirected from Schwarz Pharma)

Belgian multinational biopharmaceutical company


UCB logo

UCB S.A. is a multinational biopharmaceutical company headquartered in Brussels, Belgium. It specializes in the research, development, and commercialization of innovative medicines and solutions to improve the lives of people with severe diseases in the fields of neurology and immunology.

History[edit]

UCB was founded in 1928 by Emmanuel Janssen as a chemical company. Initially, it focused on industrial chemicals, but over the decades, it shifted its focus towards pharmaceuticals. The company made significant strides in the pharmaceutical industry in the 1950s and 1960s, leading to its current status as a leader in biopharmaceuticals.

Research and Development[edit]

UCB is committed to advancing scientific research and development. The company invests heavily in R&D, with a focus on discovering and developing new therapies for neurological disorders and autoimmune diseases. UCB's research facilities are located in several countries, including Belgium, the United States, and the United Kingdom.

Neurology[edit]

In the field of neurology, UCB has developed treatments for conditions such as epilepsy, Parkinson's disease, and restless legs syndrome. The company's flagship product in this area is levetiracetam, marketed under the brand name Keppra, which is used to treat epilepsy.

Immunology[edit]

UCB's immunology division focuses on developing therapies for autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. One of its notable products is certolizumab pegol, marketed as Cimzia, which is used to treat several inflammatory conditions.

Global Presence[edit]

UCB operates in over 40 countries worldwide, with major markets in Europe, North America, and Asia. The company employs thousands of people globally and collaborates with various academic and research institutions to advance its scientific goals.

Corporate Social Responsibility[edit]

UCB is committed to corporate social responsibility and sustainability. The company engages in various initiatives to reduce its environmental impact, promote ethical business practices, and support communities where it operates.

Related pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=UCB_(company)&oldid=6292634"